- Completing the reincorporation of Biomira into the United States as
Conference Call and Webcast
Oncothyreon's management will discuss the Company's fourth quarter and full year 2007 financial results as well as general business updates during a conference call beginning at 1:30 p.m. PT/ 4:30 p.m. ET today, Monday, March 10, 2008. To listen to a webcast of the discussion, visit http://www.oncothyreon.com.
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.
In order to provide our investors with an understanding of our current results and future prospects, this release may contain statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Oncothyreon's expectations regarding expenses related to manufacturing and process development activities and clinical development activities, revenues resulting from Merck's purchase of Stimuvax supplies, and the use and adequacy of cash resources.
Forward-looking statements involve risks and uncertainties related to
our business and the general economic environment, many beyond our control.
These risks, uncertainties and other factors
|SOURCE Oncothyreon Inc.|
Copyright©2008 PR Newswire.
All rights reserved